BCAT vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. Despite a current price of $14.67 and a seemingly low P/E of 9.72, the complete lack of profitability across all margin metrics, an unsustainable 226.7% dividend payout ratio, and missing key financial data raise serious red flags. The stock's technical trend is deeply bearish, and insider sentiment is weak, further undermining confidence. While the 21.33% dividend yield appears attractive, it is not supported by earnings or cash flow, making it highly vulnerable to cuts.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
BCAT vs BRK-B: Head-to-Head Comparison
This page compares BlackRock Capital Allocation Term Trust (BCAT) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.